To assess the
potential impact of centralized histopathological review on prostate cancer
management. Methods: 1) Biopsy slides of 277 men with newly diagnosed prostate
cancer between January 2010 and March 2014 from 22 centers were referred to our
tertiary referral center for centralized histopathological review.
The biopsy
Gleason score and D’Amico prognostic risk group were compared between those of
the referring pathologists and those after assessment by a centralized
histopathological review committee consisting of two specialized
uro-pathologists.
Alterations in
biopsy Gleason score and D’Amico prognostic risk group between referring
pathologists and centralized histopathological committee were subdivided into
treatment changes (i.e., lymph-node dissection, nerve sparing surgery, or
active surveillance) and diagnostic changes (bone scintigraphy).
No comments:
Post a Comment